Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria
- PMID: 29479042
- PMCID: PMC5929912
- DOI: 10.2176/nmc.oa.2017-0215
Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria
Abstract
The criteria for surgical cure of acromegaly have become more stringent during the past decades and a change from Cortina to new consensus criteria has recently been proposed. However, the superiority of the new consensus over Cortina criteria with respect to postoperative metabolic parameters remains to be ascertained. We retrospectively assessed metabolic parameters, the body habitus, and other health-related parameters of 48 patients with surgically controlled acromegaly who met the Cortina criteria [normalized insulin-like growth factor-1 (IGF-1) level and nadir growth hormone (GH) level <1.0 ng/ml during postoperative oral glucose tolerance test]. The 48 patients were divided into two groups. Group A (n = 33) met the new consensus criteria (normalized IGF-1 and nadir GH level <0.4 ng/ml). Group B (n = 15) met Cortina criteria, but their nadir GH ranged from 0.4 to 1.0 ng/ml. In both groups, the level of triglyceride and homeostasis model assessment-insulin resistance (HOMA-IR) was significantly decreased 1 year after the operation (P < 0.05). High-density lipoprotein cholesterol showed a significant increase only in group B (P = 0.02). However, the two groups did not differ with respect to the postoperative improvement rate of these parameters and the other health-related parameters including body mass index, blood pressure, anterior pituitary function, and self-estimated quality of life scale. In conclusion, our findings show that with respect to changes in metabolic parameters and the body habitus assessed 1 year after surgery, the stricter consensus criteria seemed not to be superior to Cortina criteria.
Keywords: Cortina criteria; acromegaly; metabolic parameters; new consensus criteria; surgical cure.
Conflict of interest statement
We declare that each of us participated sufficiently in the work to take public responsibility for this paper content. Moreover, we declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the paper reported. All authors who are members of The Japan Neurological Society have registered online self-reported COI Disclosure Statement Forms through the JNS member website.
Figures


Similar articles
-
Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.Endocr J. 2016 May 31;63(5):469-77. doi: 10.1507/endocrj.EJ15-0569. Epub 2016 Mar 5. Endocr J. 2016. PMID: 26949262
-
[Lowered ghrelin levels in acromegaly—normalization after treatment].Endokrynol Pol. 2005 Nov-Dec;56(6):862-70. Endokrynol Pol. 2005. PMID: 16821203 Clinical Trial. Polish.
-
Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.J Clin Endocrinol Metab. 2004 Feb;89(2):658-61. doi: 10.1210/jc.2003-030915. J Clin Endocrinol Metab. 2004. PMID: 14764777
-
Review of Cortina criteria for the diagnosis of acromegaly.J Endocrinol Invest. 2005;28(11 Suppl International):70-2. J Endocrinol Invest. 2005. PMID: 16625849 Review.
-
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.J Neurosurg. 2013 Dec;119(6):1467-77. doi: 10.3171/2013.8.JNS13224. Epub 2013 Sep 27. J Neurosurg. 2013. PMID: 24074496 Review.
Cited by
-
Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.Endocrine. 2019 Feb;63(2):348-360. doi: 10.1007/s12020-018-1797-8. Epub 2018 Nov 5. Endocrine. 2019. PMID: 30397873 Review.
References
-
- Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667–674, 2004 - PubMed
-
- Hazer DB, Işık S, Berker D, et al. : Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg 119: 1467–1477, 2013 - PubMed
-
- Giannella-Neto D, Wajchenberg BL, Mendonça BB, Almeida SF, Macchione M, Spencer EM: Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients. J Endocrinol Invest 11: 57–60, 1988 - PubMed
-
- Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83: 3411–3418, 1998 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous